An acyl-substituted oxazinoquinazoline compound, its preparation method and its application
A compound, methyl technology, applied in the field of medicine, can solve problems such as narrow therapeutic window, unsatisfactory use effect, and reduced curative effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
specific Embodiment approach
[0163] The intermediates involved in the compounds of the present invention can be prepared by the following methods, but are not limited to the following methods. The synthesis of some intermediates of the present invention can refer to the method of patent CN104530063. For simple replacement of some functional groups, those skilled in the art can make corresponding adjustments to obtain corresponding intermediates according to the knowledge in the field of chemical synthesis. The following invention provides the preparation route of the intermediates, the intermediates involved in the compounds of the present invention can be prepared by the following schemes, but not limited to the following schemes.
[0164] The synthesis of the intermediate compound shown in formula VIII
[0165] Intermediate N-(3-bromophenyl)-3,4-dihydro-2H-[1,4]oxazino[2,3-f]quinazolin-10-amine (VIII-1)
[0166]
[0167] Step 1) Preparation of 5-(2-hydroxyethoxy)-6-nitroquinazolin-4(3H)-one (II)
...
Embodiment 1
[0232] 1-(10-((3-bromophenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)propane- Preparation of 2-en-1-one
[0233]
[0234] N-(3-bromophenyl)-3,4-dihydro-2H-[1,4]oxazino[2,3-f]quinazolin-10-amine (VIII-1) (178mg, 0.5mmol) was dissolved in tetrahydrofuran, acryloyl chloride (45.3mg, 0.5mmol) was added, stirred at room temperature until the reaction was completed, quenched with potassium carbonate aqueous solution, extracted with ethyl acetate, concentrated organic phase and purified by silica gel column chromatography to obtain off-white 164 mg solid, 80% yield. 1 H NMR (500MHz, DMSO-d 6 )δ10.91(s,1H),8.82(s,1H),8.18(s,1H),7.95-7.90(m,1H),7.68-7.65(m,1H),7.56(dd,J=8.0, 0.9Hz, 1H), 7.52-7.45(m, 2H), 6.78-6.81(m, 1H), 6.35-6.30(m, 1H), 5.95-5.91(m, 1H), 4.71(t, J=4.5Hz ,2H),4.10(t,J=4.5Hz,2H); 13 C NMR (125MHz, DMSO) δ164.73, 159.84, 151.01, 144.14, 138.83, 133.14, 131.11, 130.22, 129.97, 129.30, 128.50, 125.08, 124.18, 121.67, 114.41, 090.070, 16; z 411.0...
Embodiment 2-82
[0236]
[0237] With reference to the preparation method of Example 1, its operation is exactly the same, and the embodiment is that R in the formula VIII with the same molar equivalent 1 X is an intermediate substituent in the table below to replace N-(3-bromophenyl)-3,4-dihydro-2H-[1,4]oxazino[2,3-f]quinazoline-10 -Amine (VIII-1), the compound of concrete implementation is shown in the table below:
[0238]
[0239]
[0240]
[0241]
[0242]
[0243]
[0244]
[0245]
[0246]
[0247]
[0248]
[0249]
[0250]
[0251]
[0252]
[0253]
[0254]
[0255]
[0256]
[0257]
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


